Abstract: With the increasing demand for drugs intended for broad, long-term treatment of non-life threatening diseases, safety is of special concern in the research and development of new drugs in these areas. This article raise the main points to consider for clinical safety evaluation in referring to the relevant ICH and FDA pre-market risk assessment guidelines.

Key words: assess, pre-marketing, clinical safety, drugs intended for long-term treatment